Carderock Capital Management Inc. Takes $4.29 Million Position in STERIS plc (NYSE:STE)

Carderock Capital Management Inc. purchased a new stake in STERIS plc (NYSE:STEFree Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 19,530 shares of the medical equipment provider’s stock, valued at approximately $4,294,000.

A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of STERIS by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 11,525,769 shares of the medical equipment provider’s stock valued at $2,786,586,000 after buying an additional 143,253 shares in the last quarter. State Street Corp boosted its holdings in shares of STERIS by 0.4% in the 1st quarter. State Street Corp now owns 4,229,089 shares of the medical equipment provider’s stock valued at $1,022,467,000 after buying an additional 17,292 shares in the last quarter. Morgan Stanley boosted its holdings in shares of STERIS by 70.7% in the 4th quarter. Morgan Stanley now owns 3,756,454 shares of the medical equipment provider’s stock valued at $693,780,000 after buying an additional 1,556,136 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of STERIS by 4.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,364,283 shares of the medical equipment provider’s stock valued at $436,660,000 after buying an additional 107,474 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of STERIS by 4.5% in the 1st quarter. Bank of America Corp DE now owns 1,295,162 shares of the medical equipment provider’s stock valued at $247,739,000 after buying an additional 55,566 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

STERIS Stock Performance

STE opened at $216.65 on Thursday. STERIS plc has a 12-month low of $180.54 and a 12-month high of $254.00. The company has a current ratio of 2.43, a quick ratio of 1.49 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $21.41 billion, a PE ratio of 37.94 and a beta of 0.79. The firm has a 50 day moving average of $227.20 and a two-hundred day moving average of $218.82.

STERIS (NYSE:STEGet Free Report) last posted its earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 earnings per share for the quarter, beating the consensus estimate of $2.17 by $0.05. The firm had revenue of $1.40 billion during the quarter, compared to analyst estimates of $1.35 billion. STERIS had a net margin of 10.48% and a return on equity of 13.67%. The business’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 EPS. On average, analysts anticipate that STERIS plc will post 8.67 EPS for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Friday, February 23rd were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 0.96%. The ex-dividend date of this dividend was Thursday, February 22nd. STERIS’s dividend payout ratio (DPR) is 36.43%.

Wall Street Analysts Forecast Growth

STE has been the subject of several research analyst reports. Stephens reaffirmed an “overweight” rating and issued a $250.00 price objective on shares of STERIS in a research report on Friday, February 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Thursday, February 8th. KeyCorp initiated coverage on shares of STERIS in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $253.00 price objective for the company. Finally, TheStreet raised shares of STERIS from a “c+” rating to a “b” rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $239.60.

Check Out Our Latest Stock Report on STERIS

STERIS Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Further Reading

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.